289.96
Schlusskurs vom Vortag:
$289.00
Offen:
$286.385
24-Stunden-Volumen:
756.86K
Relative Volume:
0.78
Marktkapitalisierung:
$37.81B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$-269.70M
KGV:
-138.74
EPS:
-2.09
Netto-Cashflow:
$-75.39M
1W Leistung:
+1.63%
1M Leistung:
+19.83%
6M Leistung:
+18.40%
1J Leistung:
+94.11%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
289.96 | 37.20B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
2023-09-29 | Eingeleitet | Raymond James | Outperform |
2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
2023-03-21 | Eingeleitet | Bernstein | Outperform |
2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
2022-06-07 | Eingeleitet | William Blair | Outperform |
2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-03-01 | Eingeleitet | Citigroup | Buy |
2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-10-04 | Hochstufung | UBS | Neutral → Buy |
2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2020-09-30 | Fortgesetzt | Berenberg | Hold |
2020-09-08 | Eingeleitet | Citigroup | Buy |
2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
2020-03-19 | Eingeleitet | Berenberg | Buy |
2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
2019-05-23 | Fortgesetzt | Goldman | Neutral |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-01-23 | Eingeleitet | UBS | Neutral |
2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-08-13 | Bestätigt | Stifel | Buy |
2018-08-07 | Hochstufung | Stifel | Hold → Buy |
2018-05-04 | Bestätigt | Stifel | Hold |
2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
3 High-Flying Stocks That Could Soar Even More - AOL.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Alnylam Issues 2024 Corporate Responsibility Report - BioSpace
Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus
Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
High Growth US Tech Stocks To Watch In May 2025 - simplywall.st
Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader
Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters
Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo
Alnylam shareholders approve executive compensation plan - Investing.com
Alnylam Pharma Re-elects Directors at Annual Meeting - TipRanks
12 Best Growth Stocks to Buy and Hold for the Long Term - Insider Monkey
Hypercholesterolemia Treatment Market Top Companies Study - openPR.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Target Price from Analysts - Defense World
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - simplywall.st
Alnylam to present key data on amyloidosis treatments By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance
Alnylam (ALNY) to Unveil Latest Transthyretin Amyloidosis Data a - GuruFocus
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress - marketscreener.com
Alnylam to Share Progress Across its Transthyretin Amyloidosis F - GuruFocus
Alnylam to present key data on amyloidosis treatments - Investing.com Australia
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
Trend Tracker for (ALNY) - news.stocktradersdaily.com
‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review
RNA Therapy Market Booms Amid Advancements in mRNA and Gene - openPR.com
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga
LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN
Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com
Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications - Pharma Voice
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to “Buy” at StockNews.com - Defense World
U.S. Transthyretin Amyloidosis Treatment Market Set to Witness - openPR.com
Coagulation factor deficiency Market: Epidemiology, - openPR.com
Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - simplywall.st
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):